UMediC Group Berhad Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

UMediC Group Berhad (KLSE:UMC) Full Year 2024 Results

Key Financial Results

• Revenue: RM54.6m (up 20% from FY 2023).
• Net income: RM8.99m (down 13% from FY 2023).
• Profit margin: 17% (down from 23% in FY 2023). The decrease in margin was driven by higher expenses.
• EPS: RM0.024 (down from RM0.028 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

UMediC Group Berhad Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) missed analyst estimates by 5.9%.

Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Healthcare industry in Malaysia.

Performance of the Malaysian Healthcare industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Before we wrap up, we've discovered 2 warning signs for UMediC Group Berhad (1 is potentially serious!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.